Clinical Trials Search Results

Display:

Title

Description with: Locations Eligibility

Full Trial Description

Custom

?

Hide Search Criteria

Show Search Criteria

Drug: midostaurin
Find trials that include: Any drugs shown

Results 1-6 of 6 for your search:

Start Over

Select All on Page Sort by: Show Results per Page

1.

Azacitidine with or without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients with Previously Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Status: Not yet active
Phase: Phase III, Phase II
Type: Treatment
Age: 60 and over
Trial IDs: S1612, NCI-2017-00436, NCT03092674

2.

Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML

Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 to 60
Trial IDs: CPKC412AUS23, NCI-2013-02275, NCT01883362

3.

Midostaurin and Decitabine in Treating Older Patients with Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: MC1483, NCI-2015-02107, NCT02634827

4.

Midostaurin in Treating Older Patients with Mutated Acute Myeloid Leukemia Post-Transplant

Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: HEMAML0022-EXT, NCI-2016-00424, NCT02723435

5.

Chemotherapy, Radiation Therapy, and Midostaurin in Treating Patients with Locally Advanced Rectal Cancer

Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10-457, NCI-2011-03089, CPKC412AUS09T, NCT01282502

6.

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy.

Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: CPKC412AUS56X, NCI-2016-01011, NCT02624570

Select All on Page

Start Over